Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Gilead Sciences, Inc.
  6. News
  7. Summary
    GILD   US3755581036

GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
62.36 USD   +0.89%
06/29Kite's CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
AQ
06/28Kite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
BU
06/27Gilead Sciences Resubmits Application for HIV Treatment Candidate
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about GILEAD SCIENCES, INC.
06/29Kite's CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Tre..
AQ
06/28Kite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Tr..
BU
06/27Gilead Sciences Resubmits Application for HIV Treatment Candidate
MT
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
BU
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
CI
06/27Gilead Sciences, Inc. - Investigational Lenacapavir Receives Positive CHMP Opinion for ..
AQ
06/27Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Negle..
BU
06/24Gilead Sciences Receives Positive CHMP Opinion for HIV Drug
MT
06/24Gilead Sciences, Inc. - Treatment With Hepcludex (Bulevirtide) Meets Primary Endpoint a..
AQ
06/24Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug R..
BU
06/24Gilead Sciences, Inc. Announces Investigational Lenacapavir Receives Positive Chmp Opin..
CI
06/24Gilead Gets CHMP Backing for Lenacapavir in Multi-Drug Resistant HIV
DJ
06/23Gilead Sciences Says Phase 3 Trial of Hepatitis Drug Meets Primary Endpoint
MT
06/23Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant..
BU
06/23Gilead Sciences, Inc. Announces Week 48 Results from the Pivotal Phase 3 Clinical Trial..
CI
More most relevant news
All news about GILEAD SCIENCES, INC.
06/29Kite's CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Tre..
AQ
06/28Kite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Tr..
BU
06/27Gilead Sciences Resubmits Application for HIV Treatment Candidate
MT
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
BU
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
CI
06/27Gilead Sciences, Inc. - Investigational Lenacapavir Receives Positive CHMP Opinion for ..
AQ
06/27Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Negle..
BU
06/24Gilead Sciences Receives Positive CHMP Opinion for HIV Drug
MT
06/24Gilead Sciences, Inc. - Treatment With Hepcludex (Bulevirtide) Meets Primary Endpoint a..
AQ
06/24Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug R..
BU
More news
News in other languages on GILEAD SCIENCES, INC.
06/27Gilead Sciences soumet à nouveau une demande pour un candidat au traitement du VIH
06/27Gilead soumet à nouveau une demande d'autorisation de mise sur le marché à la Food and ..
06/24Gilead Sciences reçoit un avis positif du CHMP pour son médicament contre le VIH
06/24Gilead Sciences, Inc. annonce que le lenacapavir expérimental a reçu un avis positif de..
06/23Gilead Sciences déclare que l'essai de phase 3 du médicament contre l'hépatite a attein..
06/23Gilead Sciences, Inc. Annonce les résultats à la 48e semaine de l'essai clinique pivot ..
06/15Les nouvelles données de Gilead Sciences soulignent que les personnes vivant avec le VI..
06/13RELIEF : nouveau désaveu aux Etats-Unis pour l'aviptadil contre la Covid-19
06/06Les données finales de l'étude de phase 3 Ascent démontrent que Trodelvy prolonge la su..
06/04Gilead Sciences, Inc. Annonce des résultats positifs de l'analyse primaire de l'étude d..
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
05/23SVB Securities Initiates Gilead Sciences at Market Perform With $68 Price Target
MT
05/23ANALYST RECOMMANDATIONS : AbbVie, Amgen, Caterpillar, HP, Nike...
05/17ANALYST RECOMMENDATIONS : AMD, CarMax, Gilead, J.B. Hunt, Vodafone...
05/17Piper Sandler Adjusts Gilead Sciences' Price Target to $69 From $73, Maintains Neutral ..
MT
05/13UBS Adjusts Gilead Sciences Price Target to $64 From $65, Maintains Neutral Rating
MT
More recommendations
Press releases
06/29Kite's CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Tre..
AQ
06/28Kite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Tr..
BU
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
BU
06/27Gilead Sciences, Inc. - Investigational Lenacapavir Receives Positive CHMP Opinion for ..
AQ
06/27Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Negle..
BU
More press releases
Analysis
GSK to buy Sierra Oncology amid pressure to boost drug pipeline
Official Publications
04/28SEC Filing 10Q-1 
04/28Press Release 
04/281st quarter results 
04/28SEC Filing 8K 
03/07SEC Filing 8K 
03/03Report 
Upcoming event on GILEAD SCIENCES, INC.
07/27/22Interim 2022 Earnings Release (Projected)
Upcoming sector events
07/27/22VERTEX PHARMACEUTICALS INCORPORATED : Interim 2022 Earnings Release (Projected)
08/04/22REGENERON PHARMACEUTICALS, INC. : Interim 2022 Earnings Release (Projected)
08/08/22BIONTECH SE : Interim 2022 Earnings Release
08/23/22WUXI APPTEC CO., LTD. : Interim 2022 Earnings Release (Projected)
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs